☆ 4.2 Article

Approach to the patient with suspected hypereosinophilic syndrome

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

相关参考文献

注意：仅列出部分参考文献，下载原文获取全部文献信息。

Review Allergy

Drug-Induced Hypersensitivity Syndrome (DIHS)/Drug Reaction With Eosinophilia and Systemic Symptoms (DRESS): Clinical Features and Pathogenesis

Natsumi Hama et al.

Summary: Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS) is a severe delayed T-cell-mediated adverse drug reaction characterized by fever, rash, facial edema, organ involvement, and hematological abnormalities. DIHS/DRESS is associated with the reactivation of chronic persistent human herpesviruses and has a high mortality rate. Identifying potential drug causes and avoiding structurally related drugs is essential. Systemic corticosteroids are the mainstay of treatment with alternative options such as immunosuppressants. HLA class I alleles have been linked to DIHS/DRESS predisposition, providing insights into prevention, risk stratification, and early diagnosis.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

添加到收藏夹

Article Allergy

An International, Retrospective Study of Off-Label Biologic Use in the Treatment of Hypereosinophilic Syndromes

Michael M. Chen et al.

Summary: Biologics may offer a safer treatment alternative for hypereosinophilic syndrome (HES). In this study, many patients improved symptoms and reduced the use of other medications through the use of biologics. Biologics were generally safe, but some medications may cause infusion reactions. Switching biologics or increasing the dose showed improved treatment response in some patients.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

添加到收藏夹

Review Allergy

Controversies in Allergy: The Potential Role of Biologics as First-Line Therapy in Eosinophilic Disorders

Evan S. Dellon et al.

Summary: With a better understanding of the role of eosinophils in diseases, targeting eosinophils has become an increasingly pursued therapeutic approach. The debate on whether targeted treatments should be used earlier in the treatment algorithm continues.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2022)

添加到收藏夹

Article Hematology

World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management

William Shomali et al.

Summary: The eosinophilias are a group of diseases that can cause organ damage. Diagnosis relies on various tests, including blood and marrow examination. Prognosis depends on identifying the subtype of eosinophilia. Treatment aims to reduce organ damage and requires individualized therapy.

AMERICAN JOURNAL OF HEMATOLOGY (2022)

添加到收藏夹

Article Dermatology

Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis

Lisa A. Beck et al.

Summary: This study reported the safety and efficacy of dupilumab treatment for moderate-to-severe atopic dermatitis (AD) for up to 4 years, and efficacy was also observed in a subgroup of patients who transitioned from weekly to every other week administration.

AMERICAN JOURNAL OF CLINICAL DERMATOLOGY (2022)

添加到收藏夹

Review Immunology

What we have learned about lymphocytic variant hypereosinophilic syndrome: A systematic literature review

Yiyun Shi et al.

Summary: This study provides a comprehensive review of the clinical characteristics, treatment responses, and outcomes of lymphocytic variant hypereosinophilic syndrome (L-HES). The results show that L-HES patients have a heavier disease burden, and the presence of CD3(-)CD4(+) lymphocytes is associated with higher numbers of eosinophils and organ involvement. Corticosteroids are the most commonly used treatment, but additional therapies are often required. In addition, there is an increased risk of lymphoma transformation in L-HES patients, which may be associated with cardiovascular involvement and the use of imatinib.

CLINICAL IMMUNOLOGY (2022)

添加到收藏夹

Article Education, Scientific Disciplines

Available and emerging therapies for bona fide advanced sys temic mastocytosis and pri mary eosinophilic neoplasms

Jason Gotlib

Summary: With the discovery of druggable targets, the historically poor prognosis of patients with advanced systemic mastocytosis and primary eosinophilic neoplasms has improved. Drugs such as midostaurin and avapritinib have shown significant improvements in patients' conditions and can reverse organ damage and disease symptoms. Furthermore, other inhibitors are currently being tested, and some have already been approved.

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2022)

添加到收藏夹

Letter Respiratory System

Similar distribution of peripheral blood eosinophil counts in European and East Asian populations from investigations of large-scale general population studies: the Nagahama Study

Hironobu Sunadome et al.

EUROPEAN RESPIRATORY JOURNAL (2021)

添加到收藏夹

Letter Allergy

Successful pregnancy in the setting of eosinophil depletion by benralizumab

Scott Manetz et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Article Allergy

CD3-CD4+ Lymphocytic Variant Hypereosinophilic Syndrome: Diagnostic Tools Revisited

Caroline Carpentier et al.

Summary: Systematically enhanced expression of T-cell surface antigens CD2, CD5, CD45RO, and CD95 by cells allows for accurate detection of CD3LCD4D L-HES. Additionally, serum CCL17/TARC levels are significantly higher in patients with L-HES compared with those with I-HES, with a threshold of 3000 pg/mL allowing for detection of all subjects with L-HES.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Review Immunology

Lessons learned from targeting eosinophils in human disease

Fei Li Kuang et al.

Summary: Eosinophils, a subset of the granulocyte lineage, play a crucial role in innate immunity and other physiological responses. Recent research has advanced our understanding of the functions of eosinophils in health and disease, highlighting their significance in maintaining homeostasis and responding to pathological conditions.

SEMINARS IN IMMUNOPATHOLOGY (2021)

添加到收藏夹

Review Hematology

Treatment of lymphocyte-variant hypereosinophilic syndrome (L-HES): what to consider after confirming the elusive diagnosis

Alastair K. Williams et al.

Summary: Lymphocyte-variant hypereosinophilic syndrome (L-HES) is a rare disease driven by aberrant T cells producing eosinophilopoietic cytokines such as interleukin-5 (IL-5). Treatment is challenging due to steroid resistance, with corticosteroids often used as first-line therapy. Additional options include interferon-alpha (IFN-alpha), anti-IL-5 monoclonal antibodies, cyclosporine, and mycophenolate, with varying effectiveness and side-effects. More prospective clinical trials are needed for patients with L-HES.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Allergy

Integrated Safety and Efficacy Among Patients Receiving Benralizumab for Up to 5 Years

Stephanie Korn et al.

Summary: The study evaluated the long-term safety and tolerability of benralizumab in adults with severe, uncontrolled eosinophilic asthma over a period of up to 5 years. The results showed that benralizumab was safe and well tolerated, with no new safety signals observed, and a significant reduction in exacerbations similar to previous studies.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2021)

添加到收藏夹

Letter Allergy

Assessment of T-cell polarization on the basis of surface marker expression: Diagnosis and potential therapeutic implications in lymphocytic variant hypereosinophilic syndrome

Emmanuel Ledoult et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2020)

添加到收藏夹

Article Gastroenterology & Hepatology

Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis

Ikuo Hirano et al.

GASTROENTEROLOGY (2020)

添加到收藏夹

Article Immunology

Eosinophilia Associated With CD3-CD4+T Cells: Characterization and Outcome of a Single-Center Cohort of 26 Patients

Caroline Carpentier et al.

FRONTIERS IN IMMUNOLOGY (2020)

添加到收藏夹

Article Allergy

Efficacy and safety of mepolizumab in hypereosinophilic syndrome: A phase III, randomized, placebo-controlled trial

Florence Roufosse et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

添加到收藏夹

Article Medicine, General & Internal

Anti-Siglec-8 Antibody for Eosinophilic Gastritis and Duodenitis

Evan S. Dellon et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

添加到收藏夹

Review Cell Biology

Gene Expression Comparison between Sezary Syndrome and Lymphocytic-Variant Hypereosinophilic Syndrome Refines Biomarkers for Sezary Syndrome

Andrea Moerman-Herzog et al.

CELLS (2020)

添加到收藏夹

Article Medicine, General & Internal

Benralizumab for PDGFRA-Negative Hypereosinophilic Syndrome

F. L. Kuang et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

添加到收藏夹

Article Allergy

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma

Sumita Khatri et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)

添加到收藏夹

Article Hematology

Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes

Sandhya R. Panch et al.

BLOOD (2018)

添加到收藏夹

Article Allergy

Long-Term Clinical Outcomes of High-Dose Mepolizumab Treatment for Hypereosinophilic Syndrome

Fei Li Kuang et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2018)

添加到收藏夹

Article Allergy

Benralizumab does not impair antibody response to seasonal influenza vaccination in adolescent and young adult patients with moderate to severe asthma: results from the Phase IIIb ALIZE trial

Pamela L. Zeitlin et al.

JOURNAL OF ASTHMA AND ALLERGY (2018)

添加到收藏夹

Article Medicine, General & Internal

Mepolizumab or Placebo for Eosinophilic Granulomatosis with Polyangiitis

M. E. Wechsler et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

添加到收藏夹

Article Microbiology

The Regulatory Function of Eosinophils

Ting Wen et al.

MICROBIOLOGY SPECTRUM (2016)

添加到收藏夹

Review Hematology

How I treat hypereosinophilic syndromes

Amy D. Klion

BLOOD (2015)

添加到收藏夹

Article Allergy

Eosinophilia in Infectious Diseases

Elise M. O'Connell et al.

IMMUNOLOGY AND ALLERGY CLINICS OF NORTH AMERICA (2015)

添加到收藏夹

Letter Oncology

Lymphocytic variant hypereosinophilic syndrome progressing to angioimmunoblastic T-cell lymphoma

Florence Roufosse et al.

LEUKEMIA & LYMPHOMA (2015)

添加到收藏夹

Article Allergy

Marked and persistent eosinophilia in the absence of clinical manifestations

Yun-Yun K. Chen et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2014)

添加到收藏夹

Article Medicine, General & Internal

The Lymphoid Variant of Hypereosinophilic Syndrome Study of 21 Patients With CD3-CD4+ Aberrant T-Cell Phenotype

Guillaume Lefevre et al.

MEDICINE (2014)

添加到收藏夹

Article Allergy

Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes

Peter Valent et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2012)

添加到收藏夹

Article Allergy

Mepolizumab as a corticosteroid-sparing agent in lymphocytic variant hypereosinophilic syndrome

Florence Roufosse et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)

添加到收藏夹

Letter Allergy

Incidence of myeloproliferative hypereosinophilic syndrome in the United States and an estimate of all hypereosinophilic syndrome incidence

Martin M. Crane et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2010)

添加到收藏夹

Article Allergy

Hypereosinophilic syndrome: A multicenter, retrospective analysis of clinical characteristics and response to therapy

Princess U. Ogbogu et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2009)

添加到收藏夹

Article Hematology

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophihc syndrome

AD Klion et al.

BLOOD (2004)

添加到收藏夹

© Peeref 2019-2024. All rights reserved.